
OPTIMA Trial at ASCO Supports Prosigna-Guided Chemotherapy Decisions in Breast Cancer
Veracyte to Present Landmark OPTIMA and ENZAMET Trial Data at ASCO 2026, Strengthening Evidence for Genomic Testing in Breast and Prostate Cancer Care Veracyte, a leading cancer diagnostics company, has announced that new data from two major Phase III clinical…











